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Abstract: The current COVID-19 pandemic has tested the resolve of the global community with more
than 35 million infections worldwide and numbers increasing with no cure or vaccine available to
date. Nanomedicines have an advantage of providing enhanced permeability and retention and have
been extensively studied as targeted drug delivery strategies for the treatment of different disease.
The role of monocytes, erythrocytes, thrombocytes, and macrophages in diseases, including infectious
and inflammatory diseases, cancer, and atherosclerosis, are better understood and have resulted
in improved strategies for targeting and in some instances mimicking these cell types to improve
therapeutic outcomes. Consequently, these primary cell types can be exploited for the purposes of
serving as a “Trojan horse” for targeted delivery to identified organs and sites of inflammation. State of
the art and potential utilization of nanocarriers such as nanospheres/nanocapsules, nanocrystals,
liposomes, solid lipid nanoparticles/nano-structured lipid carriers, dendrimers, and nanosponges for
biomimicry and/or targeted delivery of bioactives to cells are reported herein and their potential use
in the treatment of COVID-19 infections discussed. Physicochemical properties, viz., hydrophilicity,
particle shape, surface charge, composition, concentration, the use of different target-specific ligands
on the surface of carriers, and the impact on carrier efficacy and specificity are also discussed.
Keywords: biomimetic drug delivery; SARS-CoV-2; COVID-19; nanotechnology; cytokine storm
syndrome; nanomedicine
1. Introduction
Towards the end of 2019, a sudden acute atypical respiratory disease was identified in the Wuhan
province of China, with most initial cases identified to have been exposed at the Huanan seafood
market at which the sale of dead seafood and live animals occurred [1]. The Chinese government
notified the World Health Organization (WHO) and closed the Huanan seafood market in January
2020. A drastic increase in the number of cases has been observed subsequently, including persons who
had not been exposed to the seafood market directly, which confirmed human to human transmission
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of the causative organism [2]. The disease initially spread to Thailand, South Korea, and Japan as a
consequence of massive Chinese migration due to celebration of the Chinese New Year. An epidemic
caused by a novel coronavirus, with the first fatality reported on 11 January 2020, had commenced [1].
The pathogen was ultimately identified as a novel enveloped RNA β coronavirus that was subsequently
named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2], and the SARS-CoV-2 tag
was assigned due to the virus exhibiting approximately 80% homology to the SARS-CoV, which caused
acute respiratory distress syndrome (ARDS) with associated high mortality during the early 2000 s [3].
In February 2020, WHO referred to the disease caused by this virus Coronavirus disease 19 or
COVID-19, and a pandemic was declared in March 2020, the impact of which has been widespread,
with >200 countries and territories being affected [4,5]. As of 5 November 2020, over 47 million cases
have been recorded worldwide resulting in more than 1.2 million deaths. Of the over 36 million cases
that have had an outcome, 97% have been reported as recoveries [5].
The primary site of infection of the SARS-CoV-2 virus has been reported as the respiratory
system possibly due to the vast surface area of the lungs that makes them highly susceptible to the
virus, if inhaled [6], and subsequent pathology involves broad systemic infection. The symptoms
associated with COVID-19 include lower respiratory tract infection and related symptoms, viz.,
dry cough, dyspnea, ARDS, and pulmonary fibrosis in addition to more general symptoms such
as fever, headache, dizziness, generalized weakness, vomiting, and diarrhea [7]. In some instances,
patients may experience fulminant and fatal hyper-cytokinemia associated with multi-organ failure
(MOF) as a result of cytokine storm syndrome [8]. In addition, patients with COVID-19 may also
experience cardiac, hepatic, renal, central nervous system, or thrombotic disease [9].
Current medical management of COVID-19 infection is largely supportive with no specific therapy
available. Several drugs, including antimalarials such as chloroquine and hydroxychloroquine [10–12],
the anti-retroviral combination lopinavir/ritonavir [13], an investigational nucleotide analog with
broad-spectrum antiviral activity initially intended to treat hepatitis C and Ebola, viz., remdesivir [14],
and the macrolide antibiotic azithromycin [11,12], have been tested in clinical trials as potential
treatment for the virus. However, none of these approaches are a definitive cure or are suitable
for prophylaxis.
Nanomedicines are treatment platforms made typically of particles designed in the nanoscale
size range to deliver active pharmaceutical ingredients (APIs) with the intention of enhancing efficacy,
safety, accuracy of diagnosis and/or adherence with targeted treatment of diseases [15]. The benefits
of using nanomedicines may be realized using the unique properties of engineered nanomaterials,
viz., their physicochemical properties, including size, shape, chemical composition, physiochemical
stability, crystal structure, surface area, surface energy, and surface roughness and/or use of a
variety of target-specific ligands on the surface(s) of these carriers [16]. For the purposes of this
review, nanoparticles are defined as any particle that exhibits nanoscale dimensions, i.e., 1–1000 nm.
The biomaterials used in the fabrication of nanomedicines must exhibit biocompatibility to minimize
potential harmful effects to patients in order to provide efficacy without adverse events. In addition,
appropriate biomaterials must be selected to ensure the adequate delivery of the payload following
administration, necessitating confirmation through quality control process of target critical quality
attributes (CQA) following manufacture [17]. Nanomaterials based on bioinspired synthesis have
been developed with the primary aim of simulating the unique properties of naturally occurring
structures of organisms and associated biosynthetic pathways [18]. The biomimetic delivery vehicles
for which the morphology, surface properties, and/or size resemble/mimic natural structures of
organisms and cell lines, such as macrophages [19], erythrocytes [20], thrombocytes [21], exosomes [22],
or pathogens [23,24], exhibit special functions for the enhancement of delivery to target tissue or
cell populations.
In this review, we categorize biomimicry into three types, viz., I, II, and III. These definitions,
which are closely adapted to previously described classifications [25], are schematically depicted in
Figure 1 using nanospheres as an example and are used in this review as defined vide infra.
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component attached. This approach has been used for target/ligand-specific techniques for treating 
cancer using liposomes as the carrier technology [29,30]. Type III or total cell membrane transfer 
systems make use of whole membrane removal from cells and encapsulation of the nanocarrier with 
the cell membrane so as to mimic the cell from which the membrane is harvested. 
2. COVID-19 Pathogenesis 
2.1. Initial Infection 
The coronavirus is a an enclosed, positive-sense, single-stranded RNA virus of approximately 
30 kb capable of infecting a wide variety of host species [31]. The virus has four structural 
components, viz., spike, nucleocapsid, envelope, and membrane proteins [32], and the appearance of 
the virus and associated proteins are depicted in Figure 2. 
Figure 1. Schematic representation of types and sources of cell-derived biomimetic nano-drug
delivery systems.
Type I, also known as the cell, involves encapsulation of nanoparticles into a cell or pathogen
for shuttling the nanoparticle to the site of action and has been suggested as a treatment option for
accessing the human immunodeficiency virus (HIV) with macrophages to treat central nervous system
infection [26–28]. Type II or sub-membrane transfer systems make use of parts of cells, such as specific
receptors, in order to detect receptor-specific substrates or perform the role of the cell component
attached. This approach has been used for target/ligand-specific techniques for treating cancer using
liposomes as the carrier technology [29,30]. Type III or total cell membrane transfer systems make use
of whole membrane removal from cells and encapsulation of the nanocarrier with the cell membrane
so as to mimic the cell from which the membrane is harvested.
2. COVID-19 Pathogenesis
2.1. Initial Infection
The coronavirus is a an enclosed, positive-sense, single-stranded RNA virus of approximately
30 kb capable of infecting a wide variety of host species [31]. The virus has four structural components,
viz., spike, nucleocapsid, envelope, and membrane proteins [32], and the appearance of the virus and
associated proteins are depicted in Figure 2.
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the cell and subsequently enter an endosome, eventually resulting in fusion of the virus and lysosome 
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into the functional sub-units S1 and S2 [32]. Specifically, sub-unit S1 is responsible for attaching the 
virus to the receptor of the host cell and sub-unit S2 for the fusion process with the cell membrane by 
the virus. Angiotensin-converting enzyme 2 (ACE-2) has been investigated as one of the functional 
receptors for SARS-CoV [40]. The entry of SARS-CoV-2 into the host cell is dependent on the presence 
of a 180-kDa spike protein that is mediated by two critical events: ACE-2 binding to the amino-
terminal region of the spike protein, and viral fusion with cellular membranes through the carboxyl-
terminal region of the spike [34]. Infection of pulmonary cells requires proteolytic activation of the 
spike protein by cleavage of polyo-basic furin [41]. The furin protease leads to expansion of SARS-
CoV-2 tropism, which is assumed to have resulted in the transferal of the virus from bats to humans 
through an intermediary host [41]. In addition to the vast surface area of the lungs that make this 
organ a likely target for SARS-CoV-2, it has been shown that 83% of ACE-2-expressing cells in the 
human lungs are alveolar epithelial type II cells, suggesting that these cells may act as a portal for 
viral invasion [6,42]. Furthermore, gene ontology enrichment analysis has revealed that ACE-2 
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Figure 2. Schematic representation of the structure of the coronavirus.
Four genera of the coronavirus, viz., α, β, γ, and δ, exist and are differentiated on the basis of
their genomic structure. Of these, the α and β infect mammals [32] and humans, and NL63 and 229E
cause croup and cold, which are classic symptoms of infections by the α genus. The inhaled virus
binds to epithelial cells in the nasal cavity and disseminates and migrates down the respiratory tract to
the lungs [33]. Distribution and expression of receptors lead to regulation of tropism, thereby initiating
pathogenesis of the disease [34]. The life-cycle of the virus is comprised of five stages and include
attachment, penetration, bio-synthesis, maturation, and finally release [35]. Immediately following
virus attachment to host receptors, penetration occurs through a process of membrane fusion and/or
endocytosis. The viral RNA is subsequently released into host cells, where it replicates in the host
cell nucleus resulting in biosynthesis of viral proteins. New particles of virus then mature and
are released into the host. Coronavirus entry into host cells is an important determinant of viral
infectivity and pathogenesis [36,37] and is also a major target for host immune surveillance and
intervention strategies [36,38,39]. To enter host cells, coronaviruses first bind to surface receptors on
the cell and subsequently enter an endosome, eventually resulting in fusion of the virus and lysosome
membranes [36,37].
The composition of the spike (S) protein (Figure 2) includes a transmembrane tri-metric
glycoprotein that protrudes extensively on the surface of the virus. The protrusion or spike is
the primary determinant of the diversity and host tropism of the coronavirus and is further bifurcated
into the functional sub-units S1 and S2 [32]. Specifically, sub-unit S1 is responsible for attaching the
virus to the receptor of the host cell and sub-unit S2 for the fusion process with the cell membrane by
the virus. Angiotensin-converting enzyme 2 (ACE-2) has been investigated as one of the functional
receptors for SARS-CoV [40]. The entry of SARS-CoV-2 into the host cell is dependent on the presence
of a 180-kDa spike protein that is mediated by two critical events: ACE-2 binding to the amino-terminal
region of the spike protein, and viral fusion with cellular membranes through the carboxyl-terminal
region of the spike [34]. Infection of pulmonary cells requires proteolytic activation of the spike protein
by cleavage of polyo-basic furin [41]. The furin protease leads to expansion of SARS-CoV-2 tropism,
which is assumed to have resulted in the transferal of the virus from bats to humans through an
intermediary host [41]. In addition to the vast surface area of the lungs that make this organ a likely
target for SARS-CoV-2, it has been shown that 83% of ACE-2-expressing cells in the human lungs are
alveolar epithelial type II cells, suggesting that these cells may act as a portal for viral invasion [6,42].
Furthermore, gene ontology enrichment analysis has revealed that ACE-2 expressing alveolar epithelial
type II cells exhibit high levels of regulatory genes for viral processes, life cycle, assembly, and genome
replication suggesting that ACE2-expressing alveolar epithelial type II cells facilitate and aid replication
of SARS-CoV-2 in the lungs [6,42].
2.2. Cellular Mechanism (Cascade) of COVID-19 Infection
ACE-2 is a trans-membrane protein that has been characterized for its homeostatic role in
counterbalancing the impact of ACE on the cardiovascular system (CVD) [43]. Angiotensin I is
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converted to angiotensin II, a highly active octa-peptide that causes contraction of blood vessels to
increase pressure and blood flow in addition to exhibiting pro-inflammation activities. ACE-2 activity
of carboxypeptidase leads to the conversion of angiotensin II into hepta-peptide angiotensin, which is
known as the functional antagonist of the angiotensin II enzyme [34]. The high expression of
ACE in the endothelial cells of the vasculature in the lungs results in a high probability of the
presence of angiotensin II within the lung cells, which contributes to interference with pulmonary
vasculature regulation [44]. Type-II alveolar pneumocytes directly mediate the innate activity of the
pro-inflammatory response of the SARS-CoV-2 in the lower respiratory tract due to the presence
of ACE-2 in these cells. Type-II pneumocytes function as cells capable of producing interleukin
(IL)-6, tumor necrosis factor (TNF)-α, granulocyte macrophage colony-stimulating factor (GM-CSF),
monocyte chemoattractant protein (MCP)-1, and IL-1β in the pulmonary system [45]. As illustrated in
Figure 3, infected lung cells cause an increment in the levels of pro-inflammatory cytokines leading to
endothelial dilation of alveolar cells, which is responsible for a decrease in the alveolar surface tension
through accumulation of surfactant in pulmonary cells, hypovolemia, increased capillary permeability,
alveolar edema, and hypoxemia [45]. Infected pulmonary tissues are also an indirect mechanism that
induces multi-system organ dysfunction, which is characterized by acute lung failure, acute kidney
injury, acute liver failure, cardiovascular diseases, as well as a wide spectrum of the hematological
abnormalities, including neurological disorders [44]. In addition, the presence of IL-6, IL-1β, and TNF-α
has an effect on the hypothalamus region of the brain, which controls body temperature [34] and
which may induce fever, which is a potential symptom of coronavirus infection. The possible infection
cascade and classification based on pathological manifestation is depicted in Figure 3.
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2.3. Mild-to-Severe Pathological Manifestations
The clinical manifestations and associated stages of the COVID-19 disease are summarized in
Table 1. In mild-to-severe cases of COVI -19 infection, patients may present with fever, dry cough,
sore throat, headache, fatigue, chest pain, dys ea, scle ain, gastrointestinal distress, nausea,
and/or vomiting [32,46]. The virus ay b t t i t l er respiratory tract in patients who
present with thes symptoms, and pronounce r l anges in pulmonary tissues may be
evident. Histological examination reveals tha patients suffering with a mild case of the disease pre nt
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with diffuse alveolar damage, exudation of fibrin, proliferation, and desquamation of type II alveolar
epithelial (type II AE) cells, formation of hyaline membranes, and the presence of macrophages and
monocytes [47]. Lung consolidation, pulmonary opacity, damage to the alveolar septa, presence
of monocytes, and lymphocytes have also been reported following chest computed tomography
(CT) scanning [48]. In patients presenting with moderate disease, pneumonia accompanied by
frequent fever and cough is evident, while in severe cases, patients present with pneumonia and
hypoxemia [32]. When patients are in critical condition, they present with ARDS, shock, myocardial
injury, encephalopathy, heart failure, coagulation dysfunction, and acute kidney injury [32].
Table 1. Staging and clinical features of COVID-19 [32].
Clinical Staging Clinical Manifestation
Asymptomatic None
Mild
Acute upper respiratory tract infection with symptoms such as fever,
fatigue, myalgia, dry cough, sore throat, runny nose, sneezing,
and/or digestive symptoms presenting as nausea, vomiting,
abdominal pain, and diarrhea
Moderate Pneumonia with frequent fever, cough with no obvious hypoxemia,chest CT with lesions (ground glass appearance)
Severe Pneumonia with hypoxemia (oxygen saturation < 92%)
Critical ARDS, acute renal damage, possibly shock, encephalopathy,myocardial damage, heart failure, and coagulation dysfunction
3. Pharmacological and Cellular Targets for Biomimetic Drug Delivery
Currently, no cure for SARS-CoV-2 exists; however, several possibilities of a cure can be postulated
and developed for the prevention of the existing threat of SARS-CoV-2. Many of the current therapeutic
strategies are based on repurposing of existing drugs, and only a few are in development, specifically for
mitigating the current pandemic [49]. Therapeutic options include the use of peptides, small molecule
drugs, monoclonal antibodies, interferon, and vaccine approaches. From a pharmacological perspective
several targets for interruption of the life cycle of the coronavirus may be explored, including pre- and
post-entry stages of infection. The targets for interrupting the life cycle can be used to develop potential
therapeutics that inhibit viral pathogenesis of SARS-CoV-2 and the use of engineered nanocarriers to
deliver these therapeutic candidates safely and effectively explored.
The steps in the lifecycle of the virus, which are potential targets for drug therapy, require
evaluation of biomimetic drugs that are able to target cellular activities such as blocking of SARS-CoV-2
entry, endocytosis and fusion with the cell membrane, inhibition of viral enzymes, suppression of
inflammation, and inhibition of viral components, including viral envelope, membrane, nucleocapsid,
and/or accessory proteins [49–51].
3.1. Blocking of Fusion and Entry of SARS-CoV-2 into Cells
3.1.1. ACE-2/S-Protein-Receptor Domain Binding Interactions
The SARS-CoV-2 virus makes use of spike proteins present on the surface of the viral envelope to
enter host cells [52,53]. This interaction between the spike proteins and ACE-2 receptors are a potential
pharmacological target for treatment of infections. Engaging the ACE-2 receptor with recombinant
human derived ACE-2 is an approach that can be explored, as the delivery of excess soluble ACE-2
may neutralize the virus through competitive binding to the SARS-CoV-2 envelope [54,55]. In addition,
viral entry into cells may be blocked by proteins, peptides, or small molecule compounds that bind to the
S protein of the virus, thereby preventing interaction of the virus with the host cell membrane [51,56,57].
Since SARS-CoV-2 enters the host cell by binding to ACE-2 at the S protein receptor-binding
domain (RBD) [58], inhibition of SARS-CoV-2 RBD/ACE2 protein–protein interaction (PPI) is potentially
a very important therapeutic target. The first-in-class peptide binder, 23-mer peptide binder (SBP1),
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was found to potentially restrict the entry process of SARS-CoV-2 into human cells through binding to
the SARS-CoV-2-RBD [59], suggesting this is a potential approach to treatment.
3.1.2. Fusion
The entry of the SARS-CoV-2 organism to host cells is facilitated primarily by two host proteases,
viz., serine protease TMPRSS2 on the surface of the cell surface, and/or cysteine proteases cathepsin
B and L (CatB/L) in endosomes [60,61]. The development of protease inhibitors could be useful to
target these proteases as treatment options for COVID-19. Camostat mesylate, aTMPRSS2 serine
protease inhibitor and a cathepsin L inhibitor, are novel agents which may be used to inhibit COVID-19
entry into host cells. The cathepsin L inhibitor, in particular, has exhibited good results in reducing
infections in human lung cell lines when administered concomitantly with camostat mesylate [50,62,63].
Nafamostat mesylate has also been shown to prevent TMPRSS2-triggered SARS-CoV-2 membrane
fusion and has been licensed for use in Japan [61].
Unlike in SARS-CoV, the S protein of SARS-CoV-2 has a furin cleavage site at the S1/S2 boundary
similar to that observed for the MERS-CoV organism [58,64] that facilitates virus entry and subsequent
infection, potentially increasing viral transmission [65]. Targeting this unique furin-like cleavage
site of the spike glycoprotein is a potential target that can be explored, and furin inhibitors such
as decanoyl-RVKR-chloromethylketone (CMK) and naphthofluoresce that could halt SARS-CoV-2
pathogenesis in vitro and in vivo are currently being evaluated [66,67].
HR1 and HR2 present in SARS-CoV-2 facilitate cell membrane fusion [61], and peptides derived
from HR2 bind to HR1, facilitating fusion of SARS-CoV-2 with host cells. Inhibition of SARS-CoV-2
by developing potent peptide-based inhibitors that specifically target the HR1–HR2 interaction at
the S2 protein of the coronavirus are in development. HR1 and HR2 derived peptides such as the
pan-coronavirus fusion inhibitor, EK1, designated for SARS-CoV-2, showed potent fusion inhibitory
effects indicating that SARS-CoV-2–HR2P may be a promising therapeutic compound for treating
SARS-CoV-2 infections [68].
3.2. Blocking Endocytosis
Targeting endocytosis is another potential strategy for developing potential candidates to treat
SARS-CoV-2 infections, since the virus undergoes endocytosis in a pH- and receptor-dependent process
following fusion with the host cell [61]. Several possible drug candidates including janus kinase (JAK)
inhibitors such as baricitinib and ouabain, a clathrin medicated inhibitor, are undergoing clinical trials in
SARS-CoV-2 positive patients [69]. Chloroquine and hydroxychloroquine have been evaluated for their
ability to inhibit viral progression of SARS-CoV-2 [70,71]. The exact molecular mechanism of action of
hydroxychloroquine for the treatment of infection remains elusive, but it is believed to be a consequence
of endosome-mediated viral entry or late stage viral replication impairment [72]. However, the results
of preliminary large-scale randomized controlled trials with chloroquine and hydroxychloroquine
have yet to show survival benefits in COVID-19 treatment, with experts discouraging the use of these
molecules for the treatment and/or post-exposure prophylaxis of COVID-19 [73,74].
3.3. Viral Enzyme Inhibition
Papain-like cysteine protease (PLpro) and 3C-like serine protease (3CLpro or Mpro) viral enzymes
are implicated in the delivery of non-structural proteins, including RNA-dependent RNA polymerase
(RdRp) and helicase, which are involved in the process of transcription and replication of the
virus [75,76]. Potential therapeutic compounds which inhibit 3CLpro and PLpro may be explored for
the treatment of COVID-19 infections.
Multiple drugs that have been developed for targeting protease, polymerase, and helicase in
other viral pathogens are now being evaluated in clinical trials for treating SARS-CoV-2 and include
remdesivir [14,77], favipiravir [78–80], and lopinavir/ritonavir [13,81]. Remdesivir is an experimental
drug originally developed as an RNA dependent RNA polymerase (RdRP) inhibitor for treating the
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Ebola virus (EBOV) and has exhibited positive efficacy against COVID-19 in a phase 3 trial, and the
USFDA has approved emergency use of remdesivir in the USA as have many other countries [82].
3.4. Suppression of Excessive Inflammatory Response
In some patients infected with the SARS-CoV-2 organism, a hyper-inflammatory response, possibly
due to deregulated cytokine production, has been observed and is referred to as an inflammatory
cytokine storm [82]. COVID-19 patients treated in intensive care units (ICU) have presented with
extremely high levels of cytokine in plasma when compared to patients treated external to the
ICU, suggesting that dysregulation of the cytokine response occurs in the severe form of COVID-19
disease [83,84]. Furthermore, SARS-CoV-2 infected patients admitted to the ICU present with increased
GM-CSF and IL6+CD4+T cells when compared to patients not yet admitted to the ICU [85,86].
Therefore, inhibition of excessive inflammatory response may reduce the severity and morbidity
of COVID-19 disease. Corticosteroids have been used to suppress systemic inflammation [49,87],
and dexamethasone has proved beneficial when used to treat critically ill COVID-19 patients, and
reduced mortality has been observed [49,88]. Therapeutic agents such as tocilizumab, which can bind
specifically to soluble IL-6 and membrane-bound IL-6 receptors, thereby inhibiting signal transduction,
may be the first IL-6-blocking antibody useful for treating COVID-19 infections [89].
3.5. Convalescent Plasma Treatment
Convalescent plasma (CP) therapy has been proposed as a potential treatment strategy for
COVID-19 infections [90,91]. The plasma from a donor who has recovered from an infection is
transfused in an attempt to develop passive humoral immunity against SARS-CoV-2-infections in
patients. A study conducted by Salazar et al. [92] showed significant reduction in mortality (p = 0.047)
was observed when CP from a donor patient was used as a source of antibodies within 28 days of
collection, and several human trials are being conducted to better understand and evaluate CP as a
method of treatment for COVID-19 [92]. Currently, The FDA only advises the use of COVID-19 CP
under emergency use authorization (EUA) or investigational CP under an investigational new drug
(IND) during a public health emergency [93].
Currently, there is no evidence to recommend that any specific COVID-19 treatment exists; however,
several drugs and potential therapeutic strategies that target different parts of the SARS-CoV-2 life
cycle in addition to host biology are under investigation, and many clinical trials are being registered
and updated at https://clinicaltrials.gov/ [94].
4. Nano-Biomimetic Drug Delivery Technologies as Potential Treatment Strategies for COVID-19
Nanotechnology has the potential to facilitate the development of diverse drug delivery systems
for the treatment of COVID-19 infections primarily due to their small size, morphology, and ability to
mimic human cell or cellular component behavior. A wide range of APIs, including antiviral, biologic,
and nucleic acid compounds, can be loaded into and delivered by nanocarriers. This approach facilitates
selection of an appropriate nanocarrier and therapeutic agent for a specific disease condition and is vital
if commercial success of a nanomedicine for the SARS-CoV-2 virus is to be achieved [95]. Biomimicry
permits use of naturally-derived cell components such as membranes, for example, and make use of
multivalent cell membrane markers simultaneously ranging from targeting to immunomodulation
of cell surface markers [96]. These features allow biomimetic nanoparticles (NP) to target and reach
physiologically inaccessible sites whilst eliminating the immune response of the reticular endothelial
cells while potentially offering alternative treatment targets in vulnerable cells in COVID-19 infections.
This concept forms the basis for evaluation and the potential application of nano biomimetics in
COVID-19 theranostics.
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4.1. Nano Macrophage-Mimetic Drug Delivery for COVID-19
Macrophages have a number of roles in human biology, including development of tissues,
homeostasis, repair, and more specifically innate immunity, which is pertinent to this review [97].
Nano macrophage-mimetic (NMM) drug delivery is influenced by the identification and selection of
receptors located on the surface of macrophages and the enhancement of the nanomedicines towards
these receptors [56]. Macrophage-inspired targeted drug delivery has been explored for the treatment
of lung cancer [98].
Macrophage-mimetic nanoparticles (MMNPs) have an antigenic exterior surface, which is similar
or the same as human macrophage cells, and are able to bind to endotoxins. Therefore, MMNPs can
act as a decoy to organisms such as bacteria and viruses, ensuring management and prevention of
infection is possible [99–101].
The use of an MMNP for treatment in a murine Escherichia coli bacteremia model revealed
a reduction in pro-inflammatory cytokine levels and inhibition of bacterial dissemination,
thereby guaranteeing survival of the infected animals [102].
Cellular nanosponges produced from human cell membranes have been used as a medical
countermeasure to COVID-19 infection [101]. Macrophages were attached to the surface of the
nanosponges and mimicked ACE-2 and CD147 target receptors, and this was verified using Western
blot analysis [101]. A dose-dependent inhibition of the viral infectivity was observed [101].
In principle, as long as the virus target remains in the identified host cell, the MMNP can
neutralize the infection by providing broad-acting coverage. These nano macrophage-mimetic
systems can neutralize viral activity during the initial stages of COVID-19 infections and decrease the
fulminant inflammation associated with COVID-19 in the later stages of the disease [101]. MMNPs have
broad-spectrum neutralization capabilities and exhibit activity against bacterial toxins and inflammatory
cytokines [102]. However, since nanoparticles are able to trigger internal inflammation whilst targeting
host cells, the particle size and surface coating on the particles are critical parameters that must be
investigated during the development of MMNPs and should range in size between 120 and 200 nm to
prevent inflammation [103].
4.2. Nano Erythrocyte-Mimetic Drug Delivery for COVID-19
The desirable properties of erythrocyte-mimetic technologies as drug delivery vehicles are based
on their structure and the surface proteins used. It is possible to exploit these properties using these
as design cues to design and develop next-generation nano biomimetic delivery platforms [104–106].
Despite significant research activity to narrow the gap between synthetic nanomaterials and biological
entities, a erythrocyte-mimicking delivery vehicle remains elusive due, in part, to the challenge of
functionalizing NP so as to mimic the complex surface chemistry of biological cell in vivo [104].
Type II and III erythrocytes have been most commonly evaluated for drug delivery and, by way
of example, a combination of photothermal effect enhanced hollow mesoporous Prussian blue (HMPB)
NP with an erythrocyte membrane camouflage and folic acid modifications has been demonstrated
successfully [107]. The nanoplatform developed was precise, exhibited controlled release and sustained
accumulation of doxorubicin (DOX) whilst demonstrating a high drug loading capacity due to the
large surface area and pore volume [107].
Similarly, erythrocyte-mimetic nanoparticles (EMNP) were developed for the treatment of
paraoxon toxicity [108] and cancers with paclitaxel (PTX) [109] and DOX [20].
Type III EMNP were developed for delivering PTX to lung tumors and significantly enhanced
perfusion into the primary tumor and, more specifically, lung metastases when co-administered with a
tumor-penetrating peptide iRGD [109]. These findings provide novel approaches for the design of
nanocarriers intended to target delivery of therapeutic compounds to tumors.
Type III EMNPs intended for the delivery of DOX were synthesized using physical encapsulation
or chemical conjugation [20], and release studies suggested that chemical conjugation resulted in a
longer duration of sustained release of DOX than physical encapsulation.
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It is generally believed the S glycoprotein located on surface of the SARS-CoV-2 virus enters
erythrocytes and binds to β chains of hemoglobin and, in some instances, interferes directly with the
heme functionality of the molecule with the ultimate effect of binding methemoglobinemia [110,111].
The subsequent reduction in the production of hemoglobin that occurs is a consequence of oxidative
stress. Hyperferritinemia and a reduction of the T4 helper cell population coupled with the production
of reactive oxygen (ROS) and reactive nitrogen species (RNS) ensues [112]. Notwithstanding the
role of immune-inflammation processes in the pathophysiology of COVID-19, hemoglobin alteration,
hypoxemia, and iron dysmetabolism represent additional factors to be investigated as theranostic
targets to consider type II and III EMNP as potential drug delivery tools.
EMNPs have the potential to combine important drug delivery properties such as biocompatibility,
colloidal stability, and long circulatory retention times, and a deeper understanding of the role
played by the erythrocyte shell and polymeric core may permit further engineered modification
of these nano-formulations to subsequently improve the systemic delivery of potential therapeutic
payloads. Furthermore, the use of EMNP may permit development of decoy targets for the SARS-Cov-2
virus and subsequently reduce the effects of some of the hematological pathology of COVID-19
infections [113,114].
4.3. Nano Platelet-Mimetic Drug Delivery for COVID-19
Reports of thrombocytopenia, pulmonary vascular leakage, thrombi, and disseminated
intravascular coagulation (DIC) in COVID-19 patients are common and are associated with an
increase in morbidity and mortality rates [115,116]. Thrombocytopenia observed in patients may be a
result of either an immune response mediated thrombocytosis leading to immune thrombocytopenia
(ITP) [116], or it may be a side effect of drugs such as heparin, azithromycin, and hydrochloroquine
used to treat COVID-19 patients [115,117]. The host organism regulates platelet production in order
to minimize the inflammatory storm and beneficial platelet–pathogen interactions, which protect
pathogens from identification by the immune cells and cytotoxic agents [116]. Three main mechanisms
of SARS-CoV-2 induced thrombocytopenia have been proposed: decreased platelet synthesis via direct
infection of the bone marrow and trauma to the lungs, increased destruction of platelets due to an
immune response, and increased consumption of platelets in the lungs [116,118,119]. The decrease
in platelet synthesis via direct infection of the bone marrow by SARS-CoV-2 results in inhibition of
hematopoiesis and blockage of platelet release from pulmonary megakaryocytes following trauma to
the lung tissue. Autoantibody and immune complexes produced following a SARS-CoV-2 infection are
deposited onto the surfaces of platelets, which are targeted for destruction by the host immune system.
Lastly, damage to the lungs following a SARS-CoV-2 infection results in increased consumption of
platelets, as they aggregate at the site of injury and form thrombi lungs [116,118,119].
The interaction between platelets and pathogens shields pathogens from an immune response
by host organisms [120], and this challenge can be overcome by use of platelet-mimetic nanoparticle
(PMNP) technology to treat infections. PMNP technology makes use of platelet membranes to disguise
API-containing nanoparticles and decrease clearance of such particles, which would otherwise be
regarded as antigenic [120]. API-containing silica or poly (lactic-co-glycolic acid) (PLGA) polymeric
nanoparticles, incorporated into platelet membranes isolated from whole blood by centrifugation,
are functionalized with a specific receptor for a target pathogen [120]. The target pathogen binds
to the specific receptors on the platelet, and the API-containing composite enters the infecting virus
and destroys it [120,121]. Specific receptors can be attached to platelet mimetics to ensure death of
pathogens [120], and this approach has been investigated for the treatment of cancer [122,123], bacterial
infection [124], and vascular damage [125].
Polymeric nanoparticles have also been used for the treatment of a variety of diseases and
conditions, but generally exhibit short in-vivo circulation times and are non-specific and incompatible
with biological tissues, thereby triggering immune responses [123]. Surface modifiers and specific
proteins, when added to nanoparticles, can improve recognition by target cells; however, if these do not
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match endogenous compounds, the result is removal of the nanoparticles via an immune response [123].
The use of a PMNP ensures longer residence time for the payload in-vivo, thereby enhancing therapeutic
outcomes by providing a specific target for the platelet-binding pathogen, and by shielding the
technology from destruction by macrophage phagocytosis due to the presence of specific membrane
proteins [120,123]. The usual platelet induced inflammatory response is eliminated when using platelet
membranes alone as opposed to whole platelets [126]. The morphology, flexibility, and ability of
platelets to aggregate and recruit additional activated platelets in order to perform their function at the
site of vascular injury makes PMNP useful in managing COVID-19 induced thrombocytopenia and
vascular damage [125].
4.4. Nano Virus-Mimetic Drug Delivery for COVID-19
Viruses can efficiently bind to host cells by specific interactions between virion proteins and
membrane lipids, proteins, and/or carbohydrate moieties on the surface of the cells. Following
attachment, virus entry into the host cells occurs via endocytosis/pinocytosis or fusion/penetration.
Furthermore viruses have developed strategies to evade the immune system of the host, and different
approaches have been established to construct biomimetic nanoparticles to take advantage of the
unique capabilities of viruses to adapt and evade recognition [127].
Four types of virus-mimetic nanoparticles, viz., virosomes, virus-like particles (VP), self-assembling
nanoparticles with surface antigens, and fully synthetic virus mimicking nanoparticle have been
described [127].
The use of virosomes entails incorporation of virus-derived proteins in lamellar spherical liposomes
consisting of phospholipid bilayers and ranging in size between 20 and 200 nm [128,129]. In general the
enveloped glycoproteins derived from influenza virus, such as hemagglutinin (HA) and neuraminidase
(NA), are reconstituted with liposomes to prepare virosomes for vaccination or delivery of different
therapeutic agents [130]. Furthermore, other enveloped viruses, such as hemagglutinating virus of
Japan (HVJ), respiratory syncytial virus (RSV), and vesicular stomatitis virus (VSV), can be used to
prepare virosomes [131–134]. In other cases, human hepatitis B virus-derived nanoparticles have been
fused with liposomes, giving rise to virosome-like particles [131,134,135]. The lipoprotein inclusion
results in structural stability of the virosomes and is responsible for disease targeting, cellular uptake,
and endolysosomal escape following internalization of the carrier. Virosomes exhibit a number of
advantages over other technologies including ease of production and modification, biodegradability,
biocompatibility, and promotion of fusion activity in the endolysosomes, whilst permitting the
delivery of different drugs and protecting biologics such as monoclonal antibodies (MAb) from
degradation [136]. Nevertheless, their broad application remains limited, largely due to the potential
risk of immunogenicity which can be partly addressed by the modification of the virosome surface with
polyethylene glycol (PEG) and/or ligands [137,138], including antibodies, in order to reduce off-target
effects [137,139].
Virus-like particles (VLPs) are assembled using viral capsids or envelope proteins derived from
viruses, and these precisely defined structures enhance the loading capacity and packaging of different
drugs whilst displaying functional moieties on their surfaces, and, importantly, VLPs can also be
formed using synthetic viral capsids [140]. Pristine VLPs can be further modified to ensure additional
functionality by tailoring VLP proteins via genetic and chemical engineering [141,142], such as,
for instance, conjugation of hydrophilic polymers to the VLP to increase stability, prolong circulation
time, reduce non-specific adsorption, or attenuate immune responses [143,144]. To overcome the
disadvantages of the natural tropism of VLPs, different chemical functionalization approaches
have been developed to conjugate different ligands on VLPs for site-specific targeting and drug
delivery [142]. Since the antigenicity of VLPs is comparable to that of the original virus, they were
initially used for vaccination [145]. VLPs for MERS-CoV (MERS-CoV-LP) have been developed
via co-expression of S, E, and M proteins in Bm5 cells and the consequent self-assembly of S
protein-displaying NP in the 100–200 nm size range from cultured cells by mechanical extrusion [146].
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A slight modification of these NPs with SARS-CoV-2 S protein permits NP attachment to ACE-2
receptors instead of dipeptidyl-peptidase 4 (DPP4), resulting in stimulation of the immune system [147].
Another self-assembling approach for MERS-CoV-RBD fused with VP2 structural protein gene of
canine parvovirus in insect cells is to produce RBD-displaying chimeric VLPs of approximately 50 nm
in size, which were able to express the RBD [148]. VLP can be engineered to deliver different drugs
including small-molecules, peptides, protein and nucleic acids where the therapeutic molecules are
retained by non-covalent interaction-mediated physical loading or chemical conjugation [149,150].
Self-assembling nanoparticles are produced by use of viral glycoproteins and natural proteins that
have the ability to form nanoparticles spontaneously, as observed with influenza HA when genetically
fused to ferritin, where the resultant fusion glycoprotein formed nanoparticles spontaneously whilst
exposing eight HA trimers on the surface [149]. Recently, a computational protein design approach was
used to develop a self-assembling nanoparticle bearing an RSV antigen [151]. In this case, a rationally
designed, self-assembling protein nanoparticle served as a scaffold for multivalent presentation of a
prefusion-stabilized variant of the F glycoprotein trimer of RSV, with a repetitive array and controllable
density, and the in silico designed and fully synthetic nanoparticle exhibited optimal stability and
limited immunogenicity [151].
Nanovaccines are fabricated by encapsulation of the CoV antigens or exposing the antigen on the
surface of the NP, thereby producing NPs of similar immunological conformation to the virus. The S
protein is the main attachment factor and immunodominant antigen in the CoV and is therefore a
prime candidate for nanovaccine development [147], indicating that structure-based assembly is the
commonly used method for the production of coronaviral nanovaccines [147].
The S protein trimers can be self-assembled by removal of a non-ionic surfactant during the
purification process when forming the NPs, and mice vaccinated with NPs synthesized for use against
SARS-CoV induced a high level of neutralizing antibodies, which increased 15-fold and 68-fold when
aluminum hydroxide and Matrix M1 were used as adjuvants, respectively [152].
5. Conclusions
The COVID-19 pandemic continues to be a global catastrophe with positive cases rapidly
increasing in number throughout the world. Consequently, the development of conventional drugs,
medicines, and vaccines, in addition to the use of novel drug delivery technologies, has gained
momentum in the fight against this pandemic. State of the art delivery technologies, such as
the use of nanospheres/nanocapsules, nanocrystals, liposomes, solid lipid nanoparticles/nano lipid
carriers, dendrimers, and nanosponges, based on biomimicry, can be harnessed for targeted delivery of
therapeutic compounds to infected individuals for the treatment of COVID-19. However, the expansions
of knowledge and understanding of the COVID-19 pandemic are emerging daily, necessitating the use
of flexible and agile strategies to curb the ongoing spread of the virus. While researchers continue
to seek treatment and/or vaccine development strategies, there is a need to continue to use existing
non-pharmacological interventions to prevent the spread of infection, which include but are not limited
to regular cleaning and disinfection of surfaces, handwashing and sanitization, physical distancing,
wearing a mask, and imposing travel restrictions.
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